Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Bach

Showing results (611-620 of 639) with videos related to

Pageof 64
Sort By:
Molecular Cancer Research : MCR|April 27, 2025
Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular VesiclesCandice L Bizzaro, Camila A Bach, Ricardo A Santos, et al.
The Journal of Urology|April 21, 1999
Improvement of pressure flow parameters with finasteride is greater in men with large prostates. Finasteride Urodynamics Study GroupP Abrams, W Schäfer, T L Tammela, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2021
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III StudySuresh S Ramalingam, Silvia Novello, Salih Zeki Guclu, et al.
The Journal of Experimental Medicine|April 11, 2025
Plasmodium falciparum infection induces T cell tolerance that is associated with decreased disease severity upon re-infectionDiana Muñoz Sandoval, Florian A Bach, Alasdair Ivens, et al.
Lung Cancer (Amsterdam, Netherlands)|July 26, 2021
Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancerDavid E Kozono, Thomas E Stinchcombe, Joseph K Salama, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2001
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplificationA D Seidman, M N Fornier, F J Esteva, et al.
Cell Death and Differentiation|January 24, 2023
Galectin-7 reprograms skin carcinogenesis by fostering innate immune evasive programsNicolás A Pinto, Martín C Abba, Lorena Laporte, et al.
Contemporary Clinical Trials|November 20, 2019
A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerationsAnne T Reutens, Karin Jandeleit-Dahm, Merlin Thomas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2015
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trialC S Fuchs, S Azevedo, T Okusaka, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2016
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancerChristian Marth, Ignace Vergote, Giovanni Scambia, et al.
Pageof 64

Showing results (611-620 of 639) with videos related to

Sort By:
Pageof 64
Molecular Cancer Research : MCR|April 27, 2025
Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular VesiclesCandice L Bizzaro, Camila A Bach, Ricardo A Santos, et al.
The Journal of Urology|April 21, 1999
Improvement of pressure flow parameters with finasteride is greater in men with large prostates. Finasteride Urodynamics Study GroupP Abrams, W Schäfer, T L Tammela, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2021
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III StudySuresh S Ramalingam, Silvia Novello, Salih Zeki Guclu, et al.
The Journal of Experimental Medicine|April 11, 2025
Plasmodium falciparum infection induces T cell tolerance that is associated with decreased disease severity upon re-infectionDiana Muñoz Sandoval, Florian A Bach, Alasdair Ivens, et al.
Lung Cancer (Amsterdam, Netherlands)|July 26, 2021
Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancerDavid E Kozono, Thomas E Stinchcombe, Joseph K Salama, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2001
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplificationA D Seidman, M N Fornier, F J Esteva, et al.
Cell Death and Differentiation|January 24, 2023
Galectin-7 reprograms skin carcinogenesis by fostering innate immune evasive programsNicolás A Pinto, Martín C Abba, Lorena Laporte, et al.
Contemporary Clinical Trials|November 20, 2019
A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerationsAnne T Reutens, Karin Jandeleit-Dahm, Merlin Thomas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2015
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trialC S Fuchs, S Azevedo, T Okusaka, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2016
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancerChristian Marth, Ignace Vergote, Giovanni Scambia, et al.
Pageof 64